Restritive and Liberal Fluid Management and Colonoscopy

March 9, 2023 updated by: Yonca Özvardar Pekcan, Baskent University

A Comparison of Restrictive and Liberal Fluid Administration During Elective Colonoscopy Under Sedoanalgesia

intraduction and aim In this study, in cases who will undergo elective day colonoscopy under sedoanalgesia; It was planned to investigate the effects of restrictive and liberal fluid administration on hemodynamics, side effects, drug levels, patient satisfaction, recovery and discharge times during the procedure.

Methods This study was planned to be conducted as a prospective, randomized (closed envelope method), controlled, double-blind study with 100 adult patients aged 18-65 years in the american sociological association (ASA I-II) risk group who will undergo colonoscopy under sedation-analgesia under elective conditions.Vascular access will be opened and randomly divided into two groups as Group R (Restrictive, 2ml/kg 0.9% Sodium cloride-NaCl during colonoscopy) and Group L (Liberal 15ml/kg 0.9% NaCl during colonoscopy). For sedoanalgesia, Midazolam 0.02 mg/kg, Fentanyl 1 μg/kg, Ketamine 0.3 mg/kg will be administered intravenous (IV), followed by 10 mg additional doses of propofol until the Ramsay sedation score (RSS) is 3-4. All colonoscopy procedures will be performed by the same gastroenterologist.

Expectations and scientific contributions This research may help to understand the effects of giving or not administering intravenous fluids (restrictive/liberal) prior to the procedure in patients undergoing elective colonoscopy under sedoanalgesia. It can provide hemodynamic stability, reduction in drug doses, reduction of side effects, rapid recovery and discharge, and reduction of costs.

Study Overview

Detailed Description

intraduction and aim Intestinal cleansing and restriction of oral fluid intake in preparation for colonoscopy, which is one of the most frequently performed diagnostic procedures, may cause adverse hemodynamic effects during the procedure. These adverse effects can be prevented by intravenous fluid therapy. In this study, in cases who will undergo elective day colonoscopy under sedoanalgesia; It was planned to investigate the effects of restrictive and liberal fluid administration on hemodynamics, side effects, drug levels, patient satisfaction, recovery and discharge times during the procedure.

Methods This study was planned to be conducted as a prospective, randomized (closed envelope method), controlled, double-blind study with 100 adult patients aged 18-65 years in the american sociological association (ASA) I-II risk group who will undergo colonoscopy under sedation-analgesia under elective conditions.

The patients will be taken to the endoscopy unit and hemodynamic monitoring will be applied. Vascular access will be opened and randomly divided into two groups as Group R (Restrictive, 2ml/kg 0.9% Sodium cloride-NaCl during colonoscopy) and Group L (Liberal 15ml/kg 0.9% NaCl during colonoscopy). For sedoanalgesia, Midazolam 0.02 mg/kg, Fentanyl 1 μg/kg, Ketamine 0.3 mg/kg will be administered intravenous (IV), followed by 10 mg additional doses of propofol until the Ramsay sedation score (RSS) is 3-4. All colonoscopy procedures will be performed by the same gastroenterologist.

During the colonoscopy procedure, patients will be given 3L/min oxygen with a face mask. Basal measurement values; heart rate, systolic arterial pressure, diastolic arterial pressure, mean arterial pressure, peripheral oxygen saturation (SpO2), respiratory rate and RSS will be recorded at regular intervals after sedation until the end of the colonoscopy attempt. Total midazolam, fentanyl, propofol, and ketamine doses, induction time, colonoscopy time, cecum intubation time, recovery time, and discharge time will be recorded. Possible hypoventilation, apnea, airway obstruction, hypotension, hypertension, arrhythmia, bradycardia, SpO2 falling below 95% and other side effects will be treated and recorded.

At the end of the procedure, the satisfaction of the gastroenterologist will be recorded. Patients with an RSS ≥2 will be admitted to the recovery unit, and patients with a postanesthetic discharge score of ≥9 will be sent home with an accompanying person. Recalls about the colonoscopy procedure by calling 24 hours after the procedure; Undesirable effects such as nausea, vomiting, pain, dizziness, drowsiness and satisfaction with the procedure will be questioned.

Expectations and scientific contributions This research may help to understand the effects of giving or not administering intravenous fluids (restrictive/liberal) prior to the procedure in patients undergoing elective colonoscopy under sedoanalgesia. It can provide hemodynamic stability, reduction in drug doses, reduction of side effects, rapid recovery and discharge, and reduction of costs.

Study Type

Interventional

Enrollment (Anticipated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Yonca Özvardar Pekcan
  • Phone Number: 1085 +902322411000
  • Email: yncapek@gmail.com

Study Contact Backup

Study Locations

    • Karşıyaka
      • İzmir, Karşıyaka, Turkey, 35540
        • Recruiting
        • Baskent University Zubeyde Hanim Practice and Research Center
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Signing the informed consent form
  2. Having irritable bowel disease, suspected colitis, unexplained iron deficiency and planning colonoscopy for screening
  3. Between the ages of 18-65
  4. According to the Physical Condition Classification of the American Society of Anesthesiologists, ASA I (a healthy person who does not cause normal systemic disorders, does not have a disease or systemic problem other than intestinal pathology) or ASA II (Person with mild systemic disorder due to a cause requiring intervention or another disease)

Exclusion Criteria:

  1. Not signing the informed consent form
  2. Not between the ages of 18-65
  3. Having epileptic seizures
  4. The use of drugs that affect the nervous system
  5. Having a history of allergic reaction to study drugs
  6. Long-term use of sedatives or sedatives
  7. Receiving general anesthesia in the last 7 days
  8. Having adrenocortical insufficiency (hormone deficiency)
  9. Pregnancy
  10. Having a psychiatric disorder
  11. Having irritable bowel disease
  12. Presence of nausea, vomiting or dizziness before the procedure
  13. Being overweight
  14. Having a bad general condition
  15. Having had bowel surgery
  16. Being in the risky patient group (>ASA II)
  17. Alcohol addiction, inappropriate usage
  18. Multiple biopsies during the procedure, unwanted bleeding, changes in the amount of fluid to be given

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group R (Restrictive)
Group R (Restrictive, 2ml/kg 0.9% NaCl during colonoscopy)
Colonoscopy
Ketamine, fentanil, midazolam, propofol
Active Comparator: Group L (Liberal )
Group L (Liberal 15ml/kg 0.9% NaCl during colonoscopy)
Colonoscopy
Ketamine, fentanil, midazolam, propofol

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of systolic blood pressure in restrictive and liberal patients in colonosopy under sedoanalgesia.
Time Frame: During colonoscopy
Systolic blood pressure will be recoded.
During colonoscopy
Comparison of diastolic blood pressure in restrictive and liberal patients in colonosopy
Time Frame: During colonoscopy
Diastolic blood pressure will be recoded.
During colonoscopy
Comparison of heart rate in restrictive and liberal patients in colonosopy
Time Frame: During colonoscopy
Heart rate will be recoded.
During colonoscopy
Comparison of spO2 in restrictive and liberal patients in colonosopy
Time Frame: During colonoscopy
spO2 will be recoded.
During colonoscopy
Comparison of procedure times in restrictive and liberal patients in colonosopy
Time Frame: During colonoscopy
Procedure times will be recoded.
During colonoscopy
Comparison of total anaesthetic doses in restrictive and liberal patients in colonosopy
Time Frame: During colonoscopy
Total anaesthetic doses will be recoded.
During colonoscopy
Comparison of nose and vomiting and other effects in restrictive and liberal patients in colonosopy
Time Frame: 24 hours
Side effects will be recorded
24 hours
Comparison of sedation levels in restrictive and liberal patients in colonosopy
Time Frame: 24 hours
Ramsey and modified post anaesthetic discharge score level will be recorded.
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient satisfaction
Time Frame: 24 hours
Patient satisfaction will be assessed using a three point scale (satisfactory, moderate, not satisfactory) at the end of the procedure and after 24 hours via phone call. The patients will also be asked whether they have experienced any side effects (nausea, vomiting, abdominal pain, hallucination, double vision, etc.), and whether they would like to have the same sedoanalgesia procedure in the future colonoscopy procedures or not.
24 hours
Gastroenterologist satisfaction
Time Frame: 24 hours
At the end of the procedure, the gastroenterologist's opinion about our sedoanalgesia method will be evaluated.using a three point scale (satisfactory, moderate or unsatisfactory)..
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yonca Özvardar Pekcan, Baskent University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 11, 2022

Primary Completion (Actual)

December 1, 2022

Study Completion (Anticipated)

March 30, 2023

Study Registration Dates

First Submitted

August 24, 2022

First Submitted That Met QC Criteria

August 27, 2022

First Posted (Actual)

August 30, 2022

Study Record Updates

Last Update Posted (Estimate)

March 10, 2023

Last Update Submitted That Met QC Criteria

March 9, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • KA22/87

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Colonoscopy

Clinical Trials on Colonoscopy

Subscribe